Abstract
TAZ is a transcriptional coactivator downstream of the Hippo signaling pathway that functions as an oncogene in many solid tumours. However, its role in haematological malignancies is largely unexplored. Multiple myeloma (MM) is an incurable blood cancer that is often characterized by amplification and overexpression of the MYC oncogene. Despite efforts, direct targeting of MYC is not yet possible; therefore, alternative strategies to inhibit MYC activity are necessary. In this study, we show that, in contrast to solid tumours, expression of TAZ is lower in MM, with decreasing expression from normal plasma cells to intermediate stages of MM to fully active disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
